Avid Bioservices Inc (CDMO)

[biopharm]

Thanks CJ and Cliff Hoyt and Lisa Stepp had some very interesting meetings about the future of PS Targeting ...just as the late Dr Phil Thorpe had after discovering liquid biopsies and flipped PS exosomes being required by medical devices for all sorts of fueling activities

_____

Cliff Hoyt to Akoya to Argonaut to conflicts of interest with our very own BODs

____

How many BOD members of Avid have not been upfront with Avid Bioservices shareholders and have competing interests elsewhere?

The facts are all going to surface ...slowly ...and maybe our new sit in of a CEO is too busy talking with Argonaut and no mind to PS Targeting FULL ADVANCEMENT ... with Oncologie that has some interesting partners that have direct ties back to more interesting parties

The value has always been PS Targeting IP and the CDMO contracts are only a payoff

Cliff Hoyt at Perkin Elmer when working with Lisa Stepp and Peregrine ...how many were silenced like Dr Wolchok and Martin Edelman ...and the list is quite compelling

For now, we see the beginning of ties from Cliff Hoyt to Akoya to Argonaut ...and we have a BOD tie to Argonaut

Hedge Funds and others are required for all this plan to work and the SEC to FBI to DOJ have quite a bit of info ...since John Springs Stafford playing a puppet and we get no real news from current BOD that suggested by their non actions that PS Targeting was not worthy

I guess Ronin would be ok with paying fines verse telling the truth now

_______

Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer

Facts
PS externalization during apoptosis and cell stress are mediated by scramblases Xkr8 and TMEM16, respectively.

Exposed PS is an evolutionarily conserved anti-inflammatory and immunosuppressive signal.

An astonishing number of pathogens causing major infectious diseases utilize PS and apoptotic mimicry to evade host immune responses.

PS signaling is highly dysregulated in the tumor microenvironment and autoimmune diseases.

PS-targeting therapeutics (e.g., AnxA5, bavituximab) can stimulate immune activity.

Acknowledgements
We thank Lisa Stepp and Joseph Shan for helpful discussions and critically reading the manuscript. We apologize to those whose work was not included owing to space and reference limitations. This work was supported by: Rutgers New Jersey Medical School; NIH-CA-165077 and New Jersey Health Foundation grants to RBB, DFG grants SFB 643 and SFB 1181 to MH, and to the University of Texas; Simmons Comprehensive Cancer Center, Cancer Prevention and Research Institute of Texas RP110441 and RP120670, and Peregrine Pharmaceuticals, Inc.

Author information
Author notes

R B Birge, S Boeltz, S Kumar, J Carlson, J Wanderley, D Calianese, M Barcinski, R A Brekken, X Huang, J T Hutchins, B Freimark, C Empig, J Mercer, A J Schroit, G Schett & M Herrmann
These authors contributed equally to this work.

Affiliations

Department of Microbiology, Biochemistry and Molecular Genetics, Cancer Center, Rutgers New Jersey Medical School, 205 South Orange Ave, Newark, NJ 07103, USA
R B Birge, S Kumar & D Calianese
Department of Internal Medicine 3â??Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), University Hospital Erlangen, 91054 Erlangen, Germany
S Boeltz, G Schett & M Herrmann
Peregrine Pharmaceuticals, 14282 Franklin Avenue, Tustin, CA 92780, USA
J Carlson, J T Hutchins, B Freimark & C Empig
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
J Wanderley
Laboratório de Biologia Celular, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil
M Barcinski
Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology Research, Dallas, TX 75390-8593, USA
R A Brekken & X Huang
Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA
R A Brekken & X Huang
Medical Research Council Laboratory for Molecular Cell Biology, University College London, Gower Street, London WC1E 6BT, UK
J Mercer
Simmons Cancer Center and the Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX 75390 USA
A J Schroit

Full link below:

https://rdcu.be/bFBr4

_____________

Akoya Biosciences was founded in 2015 to commercialize the CODEX System to enable ultra-high multiplexing for biomarker discovery. The fundamental CODEX technology was developed in the lab of Dr. Garry Nolan at Stanford University, who has served as a pioneer in technological and computational methods to enable a better understanding of tissue architecture and its contribution to disease pathology.

The Phenopticsâ?¢ technology was originally conceived and developed by Cambridge Research & Instrumentation, co-founded by Peter Miller and Cliff Hoyt, acquired by Caliper in 2010, which was subsequently acquired by PerkinElmer in 2011. The Phenopticsâ?¢ technology was promptly adopted as the industry standard for multiplexed tissue analysis for translational and clinical research.

The partnership between PerkinElmer and Telegraph Hill Partners, announced in November of 2018, created the current Akoya Biosciences. This combined portfolio of complementary technologies will continue to fuel groundbreaking advancements in cancer immunology, immunotherapy and a wide range of pathology research.

https://www.akoyabio.com/company/about-company-history

___________

Akoya Biosciences together with our strategic partners are leading the emerging field of tissue biomarker analysis.

Ultra-high multiplexing biomarker analysis and discovery
High-throughput workflows for true quantitative pathology
Revealing basic cell-to-cell biology in intact tissues
Stratification and drug mechanism of action in clinical trials

PerkinElmer
PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.3 billion in 2017, has about 11,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index.


Argonaut Manufacturing Services, Inc.
Argonaut provides contract manufacturing in the life science and biotech arena for clients looking to leverage their supply chain. With experience supporting product launch, scale-up and revitalization, Argonaut houses over 7,500 sq.ft. of clean room production area and 3,000 sq. ft. of â??research use onlyâ? manufacturing space at their headquarters in Carlsbad, CA. Argonaut is backed by the venture capital team, Telegraph Hill Partners.


BioLegend
BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services, including assay development, sample testing, and conjugation. BioLegend headquarters in San Diego, CA operates under an ISO 13485:2003 certified quality management system.


Indica Labs Inc.
Indica Labs software solutions provide fast, quantitative evaluation of whole slide tissues using HALO and HALO AI for image analysis and HALO Link to manage images, data, and facilitate collaboration. With unmatched ease-of-use and scalability, pharmaceutical, healthcare, and research organizations worldwide are using HALO for high-throughput, whole-slide image quantification in areas such as oncology, immuno-oncology, neuroscience, ophthalmology, metabolism, respiratory and toxicological pathology.


Keyence
Keyence is a leading supplier of sensors, measuring systems, laser markers, microscopes, and machine vision systems worldwide, Keyence is at the forefront of factory automation. Keyence strives to develop innovative and reliable products to meet the needs of our customers in every manufacturing industry. Keyence has steadily grown since 1974 to become an innovative leader in the development and manufacturing of industrial automation and inspection equipment worldwide. Our products consist of code readers, laser markers, machine vision systems, measuring systems, microscopes, sensors, and static eliminators. Today, Keyence serves over 250,000 customers in 100 countries around the world, where our name stands for innovation and excellence. Keyence Corporation of America is located in Itasca, IL.


VIB
VIB, a life sciences research institute based in Flanders, Belgium, performs basic research with a strong focus on translating scientific results into pharmaceutical, agricultural and industrial applications.


Visiopharm
Visiopharm is a world leader in Augmented Pathologyâ?¢ solutions. Leading biopharmaceutical companies, contract research organizations (CROs), academic medical centers, and hospital diagnostic pathology labs all over the world utilize the Oncotopix platform for tissue-based research and diagnostics. Oncotopix provides scientists and pathologists with a scalable software solution that fits the needs and volumes of both research and diagnostic labs. Over the past 16 years Visiopharm has grown into an international business with over 800 installations and countless more users. Visiopharm software is featured in over 1,350 scientific publications since 2010 and is compatible with leading slide scanning systems and data management software. A growing network of authorized distributors and integration partners support the growth of Visiopharm solutions on several continents including North America, Europe, and Asia. Our headquarters is in the Medicon Valley of Denmark, with a branch office in the United Kingdom and a North American office in Broomfield, Colorado.


Ximedica, Inc.
Ximedica is ISO 13485:2012 Certified and FDA Registered. As a full-service development firm, Ximedica has an exclusive focus on medical products and over 25 years of experience developing medical devices, combination products and consumer healthcare products.

https://www.akoyabio.com/company/our-partners

__________